Company

Celtarys is a newly created company focused on the development of innovative chemical tools that improve the efficiency of the High Throughput Screening (HTS) process in early drug discovery:

 

Our proprietary technology allows the synthesis of fluorescent ligands with excellent performance features in terms of affinity, potency and selectivity that can be used in a variety of biological assays, from competitive binding assays to microscopy or kinetic studies.

Team

Our patented proprietary technology is based on the scientific work of the research group of Prof. Eddy Sotelo, which combines a long-tracked expertise in medicinal chemistry & chemical biology with a deep knowledge of GPCR structure.

We count also with the expertise in pharmacology and HTS of the group of Prof. Mabel Loza, a worldwide leader in early drug discovery collaborative projects with pharma companies.

Celtarys has a multidisciplinary and balanced team with different profiles that provide expert knowledge in each area necessary to develop and market novel products, designed from the real unmet needs in the complex early drug discovery scenario.

Eddy SoteloCo-founder and Scientific Leader
Maria Majellaro Co-founder and CSO
Gonzalo Pazos Business Developer
Sonia Martínez ArcaCo-founder and CEO
 

Our Collaborators

Celtarys Research collaborates with several academic research groups and companies expert in drug discovery research.

  • Professor Ago Rinken
    The GPCR Workgroup
    Institute of Chemistry in the University of Tartu
  • Dr. Miguel Abal
    ONCOMET
    Health Research Institute of Santiago de Compostela
  • Molecular  Neuropharmacology
    Dr. Gemma Brugal
    Molecular Neuropharmacology
    University of Barcelona
  • Department of Pharmacy and Pharmacautical Sciences
    Dr. Marialessandra Contino
    Department of Pharmacy and Pharmacautical Sciences
    University of Bari Aldo Moro

Celtarys is part of Scientist.com the world’s largest AI-powered marketplace for medical research.

 

Partners

Celtarys Research has been selected and funded under the Proof-of-Concept Ignicia Program of the Galician Agency for Innovation, GAIN